Quick Facts
  • wavy circle icon with check mark inside
  • magnifying glass with heart icon
  • gender symbols interlocked icon
  • chat box with different language translations icon
  • pin location icon
    Primary Location:
    UCLA Jonsson Comprehensive Cancer Center

Get to Know Dr. Solomon I. Hamburg

Dr. Solomon Hamburg at the UCLA Medical Center has been treating cancer patients for more than 40 years, focusing on abdominal malignancies such as peritoneal mesothelioma.

Hamburg joined UCLA Health in 2017 after being a partner at Tower Hematology Oncology Group, affiliated with nearby Cedars-Sinai Medical Center. His primary office today is Encino Cancer Care.

As a hematology specialist, Hamburg sees patients with all types of cancer, but he has particular interest in the treatment of gastrointestinal malignancies. He treats liver and blood cancers known as myeloproliferative neoplasms, along with coagulation disorders.

Hamburg has expertise in stem cell transplantation and conducts extensive research on conditions involving the scarring of bone marrow.

As president of Tower Cancer Research Foundation, he has raised more than $20 million for basic science cancer research in recent years. The money has been distributed to various Southern California institutions.

Contact Dr. Solomon I. Hamburg

Specialties of Dr. Solomon I. Hamburg

  • Hematology
  • Oncology
  • Gastrointestinal malignancies
  • Liver cancer
  • Blood cancers
  • Stem cell transplants

Dr. Solomon I. Hamburg’s Experience and Medical Education

  • Ronald Reagan UCLA Medical Center
  • Cedars-Sinai Medical Center
  • New York University School of Medicine (M.D.)
  • UCLA School of Medicine (Fellowship)
  • New York Hospital-Cornell University Medical Center (Residency)

Awards and Certifications

  • Board certified in internal medicine, hematology and medical oncology
  • Super Doctors, Southern California
  • Alpha Omega Alpha Award
  • American Society of Hematology (Member)

Publications of Dr. Solomon I. Hamburg

  • Talpaz, M. et al. (2018, August 7). Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. Journal of Hematology & Oncology.
  • Simsir, S. et al. (2010, January). Heart transplantation using bivalirudin as anticoagulant. Interactive Cardiovascular and Thoracic Surgery.
  • Jhawer, M. et al. (2007, February). Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Investigational New Drugs.